# An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B

> **NCT00124241** · PHASE2 · COMPLETED · sponsor: **Novartis**

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** telbivudine
- **DRUG:** lamivudine

## Key facts

- **NCT ID:** NCT00124241
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2003-02
- **Final completion:** 2005-11
- **Target enrollment:** — (—)
- **Last updated:** 2015-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124241, "An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00124241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*